| INTRODUCTION
Genetic heterogeneity, phenotypic variability, and disease rarity (with consequent lack of familiarity) are all factors that make the traditional diagnostic approach to genetic disorders, whereby a specific gene is selected for sequencing based on the clinical phenotype, very challenging. Whole exome sequencing, with its ability to interrogate many genes in both hypothesis-driven and hypothesis-free approaches, has revolutionized the diagnostic process, and clinical exome sequencing (CES) is now a widely adopted diagnostic test. For the purposes of manuscript terminology, CES can be performed as a first-tier test without performing any prior diagnostic workup, which is commonly, referred to as a "naïve" CES. It can also be performed as a "reflex" CES following prior inconclusive diagnostic workup consisting of imaging studies and/or laboratory studies and/or other genetic tests (whole genome array CGH, single gene testing or NGS multigene panels).
The diagnostic yield of CES, commonly estimated at~25%, is high compared to other diagnostic tools, including molecular karyotyping, which is officially endorsed by professional societies as a first-tier test in patients with developmental delay and those with congenital anomalies. Although CES has not yet been endorsed by professional societies as a first-tier test for patients with suspected Mendelian disorders, recent studies support such an indication for CES and suggest that earlier CES is associated with more favorable cost/benefit ratio (Stark et al., 2018) .
In 2015, we reported a high diagnostic yield of CES based on our local experience with the first 149 patients undergoing this testing (Yavarna et al., 2015) . The relatively high diagnostic yield appeared to correlate with the frequency of homozygous recessive etiologies, which accounted for the majority of cases. This is not surprising since the Middle Eastern population is characterized by a high level of consanguinity, which was found to strongly predict a positive CES result in that study. Since that study, several others have confirmed a relatively high molecular diagnostic yield of CES in Middle-Eastern families (Alfares et al., 2017; Al-Shamsi, Hertecant, Souid, & Al-Jasmi, 2016; Anazi et al., 2017; Charng et al., 2016; Fattahi et al., 2016; . In this follow-up study, we expand the reporting of CES from more than 500 previously unpublished cases. In addition to confirming the trends observed in the smaller cohort, the large size of this cohort allowed us to report substantially more novel variants, including those in genes that we propose as novel candidate genes.
Our expanded cohort also allowed us to observe the time-saving advantage of "naïve" versus "reflex" CES.
| PATIENTS AND METHODS

| Patients
This study includes patients referred to the Clinical and Metabolic Genetics, Pediatrics Department at Hamad Medical Corporation (HMC) from April 2014 to December 2016. Patients were referred for a variety of reasons, including neurocognitive/neurodevelopmental or neuromuscular disorders, multiple congenital anomalies or disorders of other organ systems, such as immunologic, endocrine, or cardiac disorders (described below and in Table 2 ). Among the 509 patients, 359 underwent CES as a first-tier test (naïve CES), while 150 patients had a prior diagnostic workup with imaging and/or laboratory studies, including other genetic tests such as whole genome array CGH, single gene testing or NGS multigene panels, which did not establish a diagnosis (reflex CES).
Patients received pre-and post-test counseling about the scope of CES and its potential to reveal information unrelated to their original disease; informed consent was obtained from all patients or guardians by local clinicians. Peripheral blood samples from patients and their parents were obtained for CES as available. Detailed clinical data including medical history, family pedigree, thorough physical and dysmorphology examination, and any clinically indicated tests, such as MRI or genetic/metabolic were collected. The CES was performed as a part of the diagnostic work up and standard of care. In the case of an inconclusive CES, reanalysis of CES was done at least 1 year after the date of completion of the original CES. This study was approved by the local IRB (Study protocol no: MRC-01-18-273). The "solved" cases in our study were determined to be diagnostic based on molecular results of CES and reanalysis of CES and clinical correlation by a group of expert clinical geneticists, genetic counselors and clinical laboratory scientists.
| CES and variant calling
DNA extracted from peripheral blood samples was sent to a molecular diagnostic laboratory and CES, bioinformatics analysis and variant confirmation and interpretation were performed as reported earlier; when ordered based on clinical indication, mitochondrial testing was performed via a separate mitochondrial genome sequencing and deletion testing assay, with final CES and mitochondrial results returned as a single, combined report (Yavarna et al., 2015) . Briefly, all variants were classified according to the ACMG guidelines (Richards et al., 2015) . To score variants for the allele frequency criteria in the guidelines, gnomAD and the GME databases were used. A proprietary method for copy number variant (CNV) analysis was used (Retterer et al., 2015) . All reported CNVs, as well as other clinically reported variants, were orthogonally confirmed using an appropriate secondary method, such as exon-level array CGH microarray.
| Statistical analysis
The significance of the diagnostic rate of trio-CES versus singleton-CES, p values was calculated by 1-tailed Fisher exact test. A p value of 0.05 was used as a significance threshold. Odds ratio and 95% confidence interval (CI) for the significance of difference in diagnostic rate were also calculated using SPSS.
| RESULTS
| Patient demographics
A total of 509 patients who presented with rare and diverse genetic disorders underwent CES. The male to female ratio was 1:1 (Female: N = 248, 49%; Male: N = 261, 51% Information Table S6 ).
| Patients and their clinical presentations
| Diagnostic yield of CES
The overall diagnostic yield by the CES in this study was 48.3% (n = 246), (naive 48.0%, n = 173/359 vs. reflex CES 48.6%, n = 73/150).
The molecular diagnostic rate for each of the phenotypic groups described above is shown in Table 2 .
The solved cases (diagnostic yield) were stratified according to the major clinical phenotypes, NC: 106 (46.0%); NM: 29 (64.4%);
MCAs: 45 (38.8%); OSMs: 66 (55.5%; Table 2 ).
The overall diagnostic yield for children younger than 5 years was 132/265 (49.0%). Of the children younger than 5 years at the time of testing (n = 265), trio-CES was performed for 32% (n = 87) of cases, and singleton-CES for 68% (n = 178) cases, respectively. The diagnostic yield of trio-CES was 53% (46/87), which was higher than for singleton-CES (85/177; 48%). The parental consanguinity in this group was 96/132 cases (72%).
The overall diagnostic yield for children aged 5-18 years was 47% (96/202). Out of the total number children aged 5-18 years (n = 202), trio-CES and singleton-CES were performed for 72 (35.0%) and 130 (65%) of cases, respectively. The diagnostic rate for trio-CES (43/72 cases; 59.0%) was significantly higher compared to singleton-CES (53/130 cases; 40.0%) (Odds ratio: 2.15 [95% CI, 1.2-3.9], p < 0.01) ( Table 3 ). The parental consanguinity in this group was 62/97 cases (65%). The presence of consanguinity and positive family history predicted a higher clinical sensitivity (56.3%) as compared with those who lacked both (37.0%; p = 0.02). (Table 4) .
| Characterization of CES molecular findings
Using CES, we identified 176 novel and 62 previously published pathogenic or likely pathogenic single nucleotide variants in known genes linked to the clinical phenotypes (Table 5, Supporting Information Tables S1-S3 ). More than half of the reported PV were homozygous variants in AR genes (60.0%) consistent with the high rate of consanguinity in the study population. Nevertheless, a considerable number of patients had PVs in AD (33%) or X-linked genes (5%), or de novo CNVs (2%) (Figure 1 ).
Out of AR cases, (60%) had homozygous variants for AR traits, 12 (2.3%) patients were compound heterozygous (Table 6 ) and three (0.5%) had two compound homozygous variants (a complex allele) in the same gene, which was consistent with their original clinical presentations (Table 7) .
Two patients were homozygous for PV in genes currently only known to be associated with autosomal dominant disorders (Table 8) .
Eleven (2.1%) patients had two molecularly-identified genetic disorders consistent with their original clinical presentation (Table 9 ). In addition, 210 variants of uncertain clinical significance (VUS) were reported.
These variants were not included in the diagnostic yield calculations.
| Novel disease gene discovery
Eleven novel candidate genes were reported as potential contributors to the clinical presentation in the respective patients. These were considered as part of the overall diagnostic yield, and results were managed and returned clinically, with appropriate counseling.
1. CLCN3 (p.G327A heterozygous, de novo): Two-year-old female who presented with optic atrophy and overweight status.
2. HSPB11 (p.L62AfsX14 homozygous, biparental): Two-year-old female with lung hypoplasia, polycystic kidneys, and cardiac hypertrophy. 
| CES shortens time to diagnosis
The average time to a definitive diagnosis from the patient's first visit to a genetic clinic was significantly shorter (p ≤ 0. PIEZO1x3  LRP5  PTH  GJC2  ELOVL4  EDNRB  COL7A1  CHRNAx2  ANK3  CUL7  AIPL1  ALDH7A1  DAG1  ACY1  CNTNAP1  B3GALNT2 x2  OCLN  CENPF x2  LONP1  VPS13B  LRBA  GFPT1  GLE1  CWF19L1x3  XYLT1  ECEL1  ATP6V0A4  SLC6A3x2  DYM  EIF2B2  SLC2A2  FKTN  FBP1  GCLC  PHKB  NBEAL2  RAB27A  SLC46A1  HPS1x2  HPS5  SLC25A15  IGHMBP2  ITPA  CC2D2Ax2  KCTD7  LIPH  MED17  MICU1x7  ATPAF2  RRM2B  GNPTG  MYBPC3  KLHL41  NEBx3  NHEJ1  NPC1  PDE6C  PEX2  PGAP3  PLEC  POMT1  LAMA1  SLC10A2x2  DNAH5  DNAH11  ASPM  RYR1  LIFR  TCTN3  TMPRSS4x2  CYP2R1  CYP2R1   ACTA1  SLC4A1  PLA2G7  KIF1A  EVC  DES  COL6A1  ABCB4  BSCL2  ANKRD11  ASXL3  BRAF  CAMTA1  CHD2  ARID1Bx2  COL11A1  TBX18  RAD21  DSG2  DYNC1H1x2 COL5A2  COL3A1  SLC1A3  LDLR  FGFR2  FOXP2  GATAD2B  GRIN2Ax2  HNRNPU  KMT2D  KAT6Bx2  KCNT1x2  LDB3  EFTUD2  MED13Lx2  MEF2Cx2  AHDC1  NF1  NOTCH1  COL1A1  PIEZO1  PIK3CD  PIK3R1  POGZ  PURA  RUNX2  SALL4  SCN2A  SETD2  SHANK3  SLC9A9  ATL1  SPECC1L  DNMT3A  TP63  TCOF1   OPA1  COL4A5  ATRX  DDX3X  USP35  HUWE1x2  KDM5C  KIAA2022  PDHA1x2  TAF1 (Continues)
| DISCUSSION
We previously reported that the diagnostic yield of CES was 60% in 149 patients from Qatar. In this larger study, as we continually enrolled a new cohort of 509 CES with rare and diverse disorders, the overall diagnostic yield of CES was 48.3% (n = 246). The lower diagnostic rate in this current study may be related to the strict use of ACMG guidelines for variant classification, which was not used in the first cohort, but may also involve other factors. Within our cohort, the highest diagnostic rate (64%) was observed for patients with neuromuscular disorders.
As expected, autosomal recessive variants accounted for the majority of identified causative variants. Consistent with our prior published experience, we note that this pattern extends to genes that had only been linked to human diseases in the autosomal dominant mode of inheritance (Monies, Abouelhoda, et al., 2017) . In addition, CC2D2Ax2  TMIE  VPS13B  SRD5A3  MCEE  LAMA2 x2  PCNT  DDCx2  PLA2G6  ISCA2  UQCRQ  C12orf57  RSPH9  SNX14  SEPN1  CLCN1  MKKS  ABCB4  SEPSECS  XYLT1  SGCA  OTOF  RNASEH2C  BCS1L  SLC24A5  TMPRSS3  PEX1  PEX5  GALC  TRAPPC9   TCOF1  SMARCB1  SYNGAP1  MBD5  MYH3  PTPN11x3  TP53  RYR1  LDB3  TPM2  MAP2K1  CSNK2A1  FLG  SATB2  TRPV4  NSD1  FGFR2  TNNI2  MYL2  TBCD  PPP2R5C  CDK13   LDLR  FOXP3  MECP2  MECP2  MECP2 enhanced autozygosity facilitated the co-inheritance of more than one homozygous disease-causing variant with resulting dual molecular diagnoses in several cases. The apparently lower incidence of these "multilocus" phenotypes compared to a previous estimate is likely related to our strict use of ACMG guidelines to call pathogenic variants. Indeed, our estimate is nearly identical to another study involving a comparable Middle Easter population that applied to the same criteria .
Eleven novel candidate genes were reported in this cohort of patients. These genes had not been reported in associated with human disease or the published data to support human disease association may not yet be definitive. While supporting data for the candidacy of these genes (e.g., model organism data, intolerance of the gene to sequence variation, tissue or developmental timing of expression, or knowledge of the gene function and pathway analysis) are suggestive, we emphasize that these remain candidates pending future confirmation through the reporting of similarly affected patients.
Others have noted the importance of reanalyzing CES to improve the diagnostic rate (Ewans et al., 2018; Shamseldin et al., 2017; Wright et al., 2018) . However, it is likely that CES will never reach from WGS in these "negative" cases, the full potential of WGS in patients who could not be diagnosed by CES remains to be seen (Alfares et al., 2018) . Testing other tissue sources as well as additional modalities at the RNA, epigenetic, and multilocus levels will likely be necessary to resolve an even higher proportion of cases.
The value of an early diagnosis for most patients is to improve management and quality of life. It is also of critical importance to the patient's family as defining a diagnosis allows specific prognostic predictions, connecting to other families and patient support groups.
Although there are limited treatments available for many patients, an earlier diagnosis may allow these patients to participate in available clinical trials.
A limitation of interpretation of variants found by CES in ME patients has been the lack of reliable control cohort data, such as esti- 
